Xortx Therapeutics Stock Price To Earning

XRTX Stock

USD 1.21 0.02 1.68%

XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

XORTX Therapeutics Company Price To Earning Analysis

XORTX Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current XORTX Therapeutics Price To Earning

170.67 X

Most of XORTX Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XORTX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

XORTX Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for XORTX Therapeutics is extremely important. It helps to project a fair market value of XORTX Stock properly, considering its historical fundamentals such as Price To Earning. Since XORTX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XORTX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XORTX Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Net Tangible Assets	Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.98	-0.99	-0.5	0.53	0.76	0.89	1.0	-0.43	-0.74	0.91	0.56	-0.15	0.97	-0.62	1.0	0.84	0.73	0.92	-0.15	0.16
Total Stockholder Equity	0.98		-0.98	-0.49	0.39	0.71	0.8	0.98	-0.45	-0.75	0.92	0.56	-0.17	0.99	-0.58	0.99	0.83	0.73	0.93	-0.17	0.22
Net Debt	-0.99	-0.98		0.44	-0.51	-0.73	-0.88	-0.99	0.38	0.7	-0.89	-0.48	0.12	-0.97	0.54	-0.99	-0.79	-0.67	-0.89	0.12	-0.12
Retained Earnings	-0.5	-0.49	0.44		-0.36	-0.77	-0.37	-0.47	0.76	0.87	-0.76	-0.87	0.8	-0.48	0.78	-0.52	-0.85	-0.86	-0.74	0.8	-0.83
Accounts Payable	0.53	0.39	-0.51	-0.36		0.67	0.83	0.52	-0.23	-0.3	0.33	0.44	0.11	0.34	-0.56	0.49	0.53	0.35	0.37	0.11	-0.11
Net Receivables	0.76	0.71	-0.73	-0.77	0.67		0.74	0.74	-0.65	-0.78	0.78	0.77	-0.35	0.65	-0.72	0.75	0.9	0.75	0.81	-0.35	0.48
Total Liab	0.89	0.8	-0.88	-0.37	0.83	0.74		0.89	-0.27	-0.54	0.68	0.46	0.08	0.78	-0.57	0.86	0.71	0.56	0.71	0.08	-0.08
Total Current Assets	1.0	0.98	-0.99	-0.47	0.52	0.74	0.89		-0.42	-0.71	0.89	0.54	-0.13	0.97	-0.61	1.0	0.82	0.71	0.9	-0.13	0.13
Short Term Debt	-0.43	-0.45	0.38	0.76	-0.23	-0.65	-0.27	-0.42		0.58	-0.61	-0.84	0.56	-0.43	0.83	-0.46	-0.73	-0.67	-0.58	0.56	-0.56
Intangible Assets	-0.74	-0.75	0.7	0.87	-0.3	-0.78	-0.54	-0.71	0.58		-0.91	-0.71	0.65	-0.73	0.62	-0.75	-0.89	-0.95	-0.92	0.65	-0.71
Net Tangible Assets	0.91	0.92	-0.89	-0.76	0.33	0.78	0.68	0.89	-0.61	-0.91		0.7	-0.53	0.92	-0.68	0.93	0.91	0.87	0.98	-0.53	0.53
Long Term Debt	0.56	0.56	-0.48	-0.87	0.44	0.77	0.46	0.54	-0.84	-0.71	0.7		-0.48	0.54	-0.94	0.57	0.9	0.78	0.72	-0.48	0.65
Deferred Long Term Liab	-0.15	-0.17	0.12	0.8	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48		-0.21	0.41	-0.2	-0.44	-0.61	-0.44	1.0	-0.8
Net Invested Capital	0.97	0.99	-0.97	-0.48	0.34	0.65	0.78	0.97	-0.43	-0.73	0.92	0.54	-0.21		-0.58	0.98	0.81	0.71	0.92	-0.21	0.21
Short Long Term Debt	-0.62	-0.58	0.54	0.78	-0.56	-0.72	-0.57	-0.61	0.83	0.62	-0.68	-0.94	0.41	-0.58		-0.63	-0.86	-0.76	-0.67	0.41	-0.42
Net Working Capital	1.0	0.99	-0.99	-0.52	0.49	0.75	0.86	1.0	-0.46	-0.75	0.93	0.57	-0.2	0.98	-0.63		0.85	0.75	0.93	-0.2	0.19
Common Stock	0.84	0.83	-0.79	-0.85	0.53	0.9	0.71	0.82	-0.73	-0.89	0.91	0.9	-0.44	0.81	-0.86	0.85		0.9	0.94	-0.44	0.58
Property Plant Equipment	0.73	0.73	-0.67	-0.86	0.35	0.75	0.56	0.71	-0.67	-0.95	0.87	0.78	-0.61	0.71	-0.76	0.75	0.9		0.88	-0.61	0.6
Capital Stock	0.92	0.93	-0.89	-0.74	0.37	0.81	0.71	0.9	-0.58	-0.92	0.98	0.72	-0.44	0.92	-0.67	0.93	0.94	0.88		-0.44	0.54
Current Deferred Revenue	-0.15	-0.17	0.12	0.8	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48	1.0	-0.21	0.41	-0.2	-0.44	-0.61	-0.44		-0.8
Short Term Investments	0.16	0.22	-0.12	-0.83	-0.11	0.48	-0.08	0.13	-0.56	-0.71	0.53	0.65	-0.8	0.21	-0.42	0.19	0.58	0.6	0.54	-0.8

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict XORTX Therapeutics

XORTX Retained Earnings

Retained Earnings

(22.47 Million)

XORTX Therapeutics reported Retained Earnings of (23.66 Million) in 2023

Based on the latest financial disclosure, XORTX Therapeutics has a Price To Earning of 170 times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to earning for all United States stocks is notably lower than that of the firm.

XORTX Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of XORTX Therapeutics from analyzing XORTX Therapeutics' financial statements. These drivers represent accounts that assess XORTX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XORTX Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	8.0M	10.1M	11.3M	134.3M	4.3M	4.1M
Enterprise Value	7.8M	10.1M	11.2M	123.9M	896.6K	851.8K

XORTX Fundamentals

	Return On Equity	-0.29
	Return On Asset	-0.33
	Current Valuation	1.59 M
	Shares Outstanding	3.22 M
	Shares Owned By Insiders	3.01 %
	Shares Owned By Institutions	6.03 %
	Number Of Shares Shorted	2.64 K
	Price To Earning	170.67 X
	Price To Book	1.80 X
	EBITDA	(4.87 M)
	Net Income	(2.16 M)
	Cash And Equivalents	13.42 M
	Cash Per Share	1.03 X
	Total Debt	11.51 K
	Debt To Equity	0.01 %
	Current Ratio	14.09 X
	Book Value Per Share	2.32 X
	Cash Flow From Operations	(6.58 M)
	Short Ratio	0.02 X
	Earnings Per Share	0.12 X
	Price To Earnings To Growth	9.08 X
	Target Price	12.17
	Beta	-0.21
	Market Capitalization	4.34 M
	Total Asset	5.47 M
	Retained Earnings	(23.66 M)
	Working Capital	3.77 M
	Current Asset	341.74 M
	Current Liabilities	109.37 M
	Net Asset	5.47 M

About XORTX Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC